[
  {
    "table_index": 1,
    "headers": [],
    "rows": [
      [
        "End Note"
      ],
      [
        "Procite"
      ],
      [
        "Reference Manager"
      ]
    ],
    "row_count": 3,
    "column_count": 1
  },
  {
    "table_index": 2,
    "headers": [
      "Population group",
      "Incidence of HCC"
    ],
    "rows": [
      [
        "Sufficient risk to warrant surveillance"
      ],
      [
        "Child-Pugh A–B cirrhosis, any etiologyHepatitis BHepatitis C (viremic or post-SVR)Alcohol associated cirrhosisNonalcoholic steatohepatitisOther etiologies",
        "≥1.0% per year"
      ],
      [
        "Child-Pugh C cirrhosis, transplant candidate",
        ""
      ],
      [
        "Non-cirrhotic chronic hepatitis BMan from endemic countryaage >40 yWoman from endemic countryaage > 50 yPerson from Africa at earlier agebFamily history of HCCPAGE-B score ≥ 10c",
        "≥0.2% per year"
      ],
      [
        "Insufficient risk and in need of risk stratification models/biomarkers"
      ],
      [
        "Hepatitis C and stage 3 fibrosis",
        "< 0.2% per year"
      ],
      [
        "Noncirrhotic NAFLD",
        ""
      ]
    ],
    "row_count": 7,
    "column_count": 2
  },
  {
    "table_index": 3,
    "headers": [
      "Test",
      "Early detection research network (EDRN) phase of validation",
      "Performance characteristics"
    ],
    "rows": [
      [
        "US plus AFP55",
        "5",
        "Sensitivity",
        "61%"
      ],
      [
        "",
        "",
        "Specificity",
        "92%"
      ],
      [
        "AFP-L3%69",
        "3",
        "Sensitivity",
        "62%"
      ],
      [
        "",
        "",
        "Specificity",
        "90%"
      ],
      [
        "DCP69",
        "3",
        "Sensitivity",
        "40%"
      ],
      [
        "",
        "",
        "Specificity",
        "81%"
      ],
      [
        "Multitarget algorithm70",
        "2",
        "Sensitivity",
        "82%"
      ],
      [
        "",
        "",
        "Specificity",
        "87%"
      ],
      [
        "GALAD71",
        "2/3",
        "Sensitivity",
        "54–72%"
      ],
      [
        "",
        "",
        "Specificity",
        "90%"
      ],
      [
        "Doylestown plus72",
        "2/3",
        "Sensitivity",
        "90%"
      ],
      [
        "",
        "",
        "Specificity",
        "95%"
      ]
    ],
    "row_count": 12,
    "column_count": 3
  },
  {
    "table_index": 4,
    "headers": [
      "Examples of expanded criteriaa",
      "Post-transplant survival"
    ],
    "rows": [
      [
        "UCSF criteria207",
        "One tumor ≤ 6.5 cm or2–3 tumors, each ≤ 4.5 cm, with total tumor volume ≤ 8 cm",
        "81% 5-year survival"
      ],
      [
        "Total tumor volume < 115 cm208",
        "Sum of volume for each tumor ≤ 115 cm3",
        "75% 4-year survival"
      ],
      [
        "Up-to-seven criteria209",
        "Diameter or largest tumor (cm) + number of tumors ≤ 7",
        "71% 5-year survival"
      ],
      [
        "Extended Toronto criteria210",
        "Biopsy demonstrating well-to-moderate differentiation for patients beyond Milan criteria andECOG performance status 0–1",
        "68% 5-year survival"
      ],
      [
        "Kyoto criteria211",
        "Number or tumors ≤ 10, maximum diameter of each tumor ≤ 5 cm, and serum DCP ≤ 400 mAU/ml",
        "65% 5-year survival"
      ]
    ],
    "row_count": 5,
    "column_count": 2
  },
  {
    "table_index": 5,
    "headers": [],
    "rows": [
      [
        "Inclusion criteria"
      ],
      [
        "HCC exceeding Milan criteria but meeting one of the following:1. Single lesion 5.1–8 cm2. 2–3 lesions each ≤ 5 cm with the sum of the maximal tumor diameters ≤ 8 cm3. 4–5 lesions each ≤ 3 cm with the sum of the maximal tumor diameters ≤ 8 cmAND absence of vascular invasion or extrahepatic disease based on cross-sectional imaging"
      ],
      [
        "Criteria for successful downstaging"
      ],
      [
        "Residual tumor size and diameter within Milan criteria (1 lesion ≤ 5 cm, 2–3 lesions ≤ 3 cm)(a) Only viable tumor(s) are considered; tumor diameter measurements should not include the area of necrosis from tumor-directed therapy.(b) If there is more than one area of residual tumor enhancement, then the diameter of the entire lesion should be counted toward the overall tumor burden."
      ],
      [
        "Criteria for downstaging failure and exclusion from liver transplant"
      ],
      [
        "1. Progression of tumor(s) to beyond inclusion/eligibility criteria for downstaging (as defined above)2. Tumor invasion of a major hepatic vessel based on cross-sectional imaging3. Lymph node involvement by tumor or extrahepatic spread of tumor4. Infiltrative tumor growth pattern5. Persistent AFP elevations > 500 ng/ml in patients who had prior AFP ≥ 1000 ng/ml"
      ],
      [
        "Timing of liver transplant in relation to downstaging"
      ],
      [
        "1. There should be a minimum observation period of 3 mo of disease stability from successful downstaging to liver transplant2. Per current UNOS policy, the patient must remain within Milan criteria for 6 mo after successful downstaging before receiving MELD exception points"
      ]
    ],
    "row_count": 8,
    "column_count": 1
  },
  {
    "table_index": 6,
    "headers": [],
    "rows": [
      [
        "Proposed factors for TACE unsuitability"
      ],
      [
        "Tumor size",
        "Beyond UNOS-DS criteria"
      ],
      [
        "Tumor appearance",
        "Multinodular, bilobar, with > 50% liver involvementInfiltrative or nodular with poorly defined margins"
      ],
      [
        "Tumor marker",
        "Marked AFP elevationsa"
      ],
      [
        "PVTT",
        "Large vessel vascular invasion, e.g., main PVTT or hepatic vein tumor thrombus"
      ],
      [
        "Liver function",
        "ALBI 2–3, especially if tumor exceeds segmental treatment zoneDeteriorating liver function over time"
      ],
      [
        "Proposed factors for Y90 unsuitability"
      ],
      [
        "Lung shunt",
        ">25 Gray in a single treatment>30 Gray cumulative in multiple treatments"
      ],
      [
        "Nontarget treatment",
        "Infusion zone includes gastric/duodenal branches unable to correct with embolization"
      ],
      [
        "PVTT",
        "Large vessel vascular invasion, e.g., main PVTT/Vp4 or hepatic vein tumor thrombusInability to deliver boosted dose and/or lack of uptake in the PVTT on99mTcmacroaggregated albumin scan"
      ],
      [
        "Liver function",
        "ALBI 2–3, especially if tumor exceeds segmental treatment zoneDeteriorating liver function over time"
      ]
    ],
    "row_count": 11,
    "column_count": 1
  },
  {
    "table_index": 7,
    "headers": [],
    "rows": [
      [
        "TACE or TARE refractoriness"
      ],
      [
        "Lack of objective response: >50% definite viable disease after 2 TACE treatments or 1 TARE treatment"
      ],
      [
        "Development of new HCC within treatment zone after 2 consecutive TACE"
      ],
      [
        "Lack of improvement for tumor markers (e.g., AFP) after 2 consecutive TACE or 1 TARE"
      ],
      [
        "Stage migration to advanced HCC, including new vascular invasion or extrahepatic metastases"
      ]
    ],
    "row_count": 5,
    "column_count": 1
  },
  {
    "table_index": 8,
    "headers": [
      "Aspect",
      "IMbrave150312",
      "HIMALAYA323",
      "REFLECT313"
    ],
    "rows": [
      [
        "Study drugs",
        "Atezolizumab + bevacizumab",
        "Sorafenib",
        "Durvalumab + tremelimumab",
        "Durvalumab",
        "Sorafenib",
        "Lenvatinib",
        "Sorafenib"
      ],
      [
        "Median OS, months (95% CI)",
        "19.2 (17.0–23.7)",
        "13.4 (11.4–16.9)",
        "16.4 (14.2–19.6)",
        "16.6 (14.1–19.1)",
        "13.8 (12.3–16.1)",
        "13.6 (12.1–14.9)",
        "12.3 (10.4–13.9)"
      ],
      [
        "HR for death (95% CI)",
        "0.66 (0.52–0.85)",
        "Durvalumab + tremelimumab vs. sorafenib: 0.78 (0.65–0.92)Durvalumab vs. sorafenib: 0.86 (0.73–1.03)",
        "0.92 (0.79–1.06)"
      ],
      [
        "Median PFS, months (95% CI)",
        "6.8 (5.7–8.3)",
        "4.3 (4.0–5.6)",
        "3.8 (3.7–5.3)",
        "3.7 (3.2–3.8)",
        "4.1 (3.8–5.5)",
        "7.3 (5.6–7.5)",
        "3.6 (3.6–3.9)"
      ],
      [
        "ORR by RECIST 1.1",
        "29.8",
        "11.3",
        "20.1",
        "17.0",
        "5.1",
        "18.8",
        "6.5"
      ],
      [
        "Common AEsa",
        "Hypertension (30%), fatigue (20%), proteinuria (20%), AST increase (20%), pruritis (20%), diarrhea (19%)",
        "Diarrhea (49%), PPE (48%), hypertension (24%), decreased appetite (24%), fatigue (19%), AST increase (17%)",
        "Diarrhea (27%), pruritis (23%), rash (22%), decreased appetite (17%), fatigue (17%)",
        "Diarrhea (15%), pruritis (14%), constipation (11%), AST increased (14%), decreased appetite (14%)",
        "PPE (47%), diarrhea (45%), fatigue (19%), hypertension (18%), decreased appetite (18%)",
        "Hypertension (42%), diarrhea (39%), decreased appetite (34%), decreased weight (31%), fatigue (30%), PPE (27%), proteinuria (25%), hypothyroidism (16%)",
        "PPE (52%), diarrhea (46%), hypertension (30%), decreased appetite (27%), fatigue (25%), decreased weight (22%)"
      ]
    ],
    "row_count": 6,
    "column_count": 4
  },
  {
    "table_index": 9,
    "headers": [
      "Aspect",
      "CELESTIAL314",
      "RESORCE315",
      "REACH-2127",
      "KEYNOTE-240316",
      "KEYNOTE-394317",
      "CheckMate 040318"
    ],
    "rows": [
      [
        "Study design",
        "Phase III: cabozantinib vs. placebo",
        "Phase III: regorafenib vs. placebo",
        "Phase III: ramucirumab vs. placebo",
        "Phase III: pembrolizumab vs. placebo",
        "Phase III: pembrolizumab vs. placebo",
        "Phase II: ipilimumab + nivolumab"
      ],
      [
        "Population",
        "Prior sorafenib, second or third line",
        "Tolerated and progressed on sorafenib, second line",
        "Prior sorafenib, second line, AFP > 400 only",
        "Prior sorafenib, second line",
        "Prior sorafenib, second line, Asia only",
        "Prior sorafenib, multiple prior lines allowed"
      ],
      [
        "Median OS",
        "10.2 vs. 8.0 m",
        "10.6 vs. 7.8 m",
        "8.5 vs. 7.3 m",
        "13.9 vs. 10.6 m",
        "14.6 vs. 13.0 m",
        "22.8 m"
      ],
      [
        "OS HR",
        "0.76 (0.63 to 0.92)",
        "0.63 (0.50 to 0.79)",
        "0.71 (0.53 to 0.95)",
        "0.78 (0.61 to 0.998)",
        "0.79 (0.63 to 0.99)",
        "N/A"
      ],
      [
        "PFS",
        "5.2 vs. 1.9 m",
        "3.1 vs. 1.5 m",
        "2.8 vs. 1.6 m",
        "3.0 vs. 2.8 m",
        "2.6 vs. 2.3 m",
        "Not reported"
      ],
      [
        "ORR",
        "4% vs. 1%",
        "10% vs. 4%",
        "5% vs. 1%",
        "18.3% vs. 4.4%",
        "12.7% vs. 1.3%",
        "32%"
      ],
      [
        "Common AEsa",
        "Diarrhea (54%), decreased appetite (48%), PPE (46%), fatigue (45%), nausea (31%), hypertension (29%), vomiting (26%)",
        "PPE (53%), diarrhea (41%), fatigue (40%), hypertension (31%), anorexia (31%), increased blood bilirubin (29%), abdominal pain (28%), increased AST (25%)",
        "Fatigue (24%), peripheral edema (24%), decreased appetite (22%), liver injury or failure (21%), nausea (19%), bleeding (19%), proteinuria (18%), hypertension (12%)",
        "AST increased (23%), blood bilirubin increased (19%), fatigue (19%), pruritis (18%), ALT increased (18%), decreased appetite (17%), diarrhea (17%)",
        "Immune-related AEs (18.1%), severe grade 3–5 immune-related AEs (3%)",
        "Pruritis (45%), rash (29%), diarrhea (24%), AST increased (20%), hypothyroidism (20%), fatigue (18%), ALT increase (16%), lipase increased (14%), adrenal insufficiency (14%), rash maculopapular (14%)"
      ]
    ],
    "row_count": 7,
    "column_count": 7
  }
]